Core Viewpoint - Microbix Biosystems Inc. reported a significant decline in revenues for the fiscal year 2025, primarily due to reduced antigen sales into China and the cancellation of a client program, resulting in a net loss of $2.2 million [1][3][6]. Financial Performance - Total revenues for 2025 were $18.6 million, a 27% decrease from $25.4 million in 2024 [3]. - Antigen revenues decreased by 10% to $12.4 million, attributed to fewer respiratory infections in China [3]. - QAPs revenues fell by 20% to $5.6 million due to the cancellation of test-development programs by a large client [3]. - Revenue from royalties increased by 15% to $598,775 [3]. - Gross margin percentage for 2025 was 53%, down from 61% in 2024, mainly due to fixed manufacturing costs being spread over fewer units [4]. - Operating expenses increased by 4% in 2025, influenced by lower investment income and increased spending on trade shows and R&D [5]. Quarterly Performance - Q4 revenue was $3.7 million, a 41% decrease from $6.3 million in Q4 2024 [8]. - Antigen sales in Q4 dropped by 55% to $1.95 million, primarily due to weaker sales to the China distributor [8]. - QAPs revenues in Q4 decreased by 5% to $1.6 million [8]. - Q4 gross margin percentage was 40%, down from 55% in the previous year [9]. - The company reported a net loss of $1.5 million in Q4 compared to a net income of $440,324 in Q4 2024 [10]. Cash Flow and Financial Ratios - Cash used in operating activities for 2025 was $80,287, a significant decline from cash provided of $4.3 million in 2024 [6]. - Cash and equivalents at the end of September 2025 were $12.1 million [6]. - The current ratio was 8.48, indicating strong liquidity, while the debt to equity ratio remained stable at 0.35 [7]. Corporate Outlook - The company is focused on pursuing new client programs and expanding its product portfolio to drive sales growth and improve gross margins [13]. - Microbix aims to create sustained shareholder value through its diagnostics business and the Kinlytic® drug program [13].

Core Insights - Microbix Biosystems Inc. is set to release its Q4 2025 financial results on December 18, 2025, prior to market opening, followed by a webinar discussion with key executives [1] Company Overview - Microbix Biosystems Inc. specializes in proprietary biological products for human health, employing over 120 skilled workers and reporting revenues of C$ 25.4 million in the last fiscal year (2024) [3] - The company supports the global diagnostics industry by providing critical ingredients and devices, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are utilized by approximately 100 diagnostics manufacturers, and its QAPs are available in over 30 countries through a network of international distributors [3] - The company is accredited with ISO 9001 & 13485, registered with the U.S. FDA, Australian TGA, and licensed by Health Canada, ensuring compliance with IVDR and CE marking [3] Product Development - Microbix also develops proprietary products such as Kinlytic® urokinase, a thrombolytic drug for treating blood clots, and reagents for molecular diagnostic testing [4]

Core Viewpoint - Microbix Biosystems Inc. has announced a Normal Course Issuer Bid (NCIB) program to repurchase up to 5% of its outstanding shares over a 12-month period, starting December 9, 2025, and ending December 8, 2026 [1][2][3]. Summary by Sections NCIB Program Details - The NCIB allows Microbix to repurchase up to 6,949,346 common shares, which is approximately 5% of the 138,986,931 shares outstanding as of November 26, 2025 [2]. - Repurchases will occur through the Toronto Stock Exchange (TSX) and alternative trading systems, with the actual number of shares repurchased determined by management [2][3]. - The maximum number of shares that can be repurchased in one day is set at 20,339, which is 25% of the average daily trading volume (ADTV) of 81,357 shares over the past six months [4]. Previous NCIB Performance - In the previous NCIB from December 9, 2024, Microbix sought approval to purchase up to 6,726,560 shares and successfully repurchased 3,661,581 shares at a volume-weighted average price of $0.369 [4]. Funding and Management Strategy - The repurchases will be financed from working capital, and all repurchased shares will be cancelled [5]. - Microbix has established a predefined automatic securities purchase plan with Ventum Financial Corp. to facilitate repurchases during internal trading blackout periods [5]. Board of Directors' Perspective - The Board believes that the current market price does not reflect the underlying value of Microbix, making the share repurchase an appropriate use of corporate funds [6]. - The NCIB is expected to benefit shareholders by increasing their proportionate equity interest as shares are cancelled [6]. Company Overview - Microbix Biosystems Inc. specializes in creating proprietary biological products for human health, generating revenues of C$ 25.4 million in its latest fiscal year [8]. - The company produces critical ingredients for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products [8][10].

Core Insights - Microbix Biosystems Inc. is addressing a cybersecurity incident involving a ransomware attack that resulted in data theft but did not disrupt operations [1][2][3] - The company has been enhancing its cybersecurity measures since early 2022, including the implementation of advanced software systems [4][8] - Microbix has a policy of not paying ransoms to hackers, aiming to discourage cybercrime [4] Company Overview - Microbix is a life sciences innovator focused on creating proprietary biological products for human health, with over 120 employees and monthly revenues targeting C$ 2.0 million or more [5][6] - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and quality assessment products [5] - Microbix's products are sold in over 30 countries and are supported by a network of international distributors [5] Cybersecurity Measures - The company has adopted the Center for Internet Security (CIS) frameworks for its cybersecurity programs [8] - Regular employee cybersecurity training and endpoint server protection for real-time threat monitoring are part of the ongoing improvements [8] - Microbix is also focusing on disaster-recovery and business-continuity planning [8]

Core Insights - Microbix Biosystems Inc. will present to investors at the Muskoka Capital Event from September 26 to 28, 2025, focusing on growth-oriented investors [1][2] - The company aims to engage in 18 one-on-one meetings with investors during the event [2] - Microbix generates revenues targeting C$ 2.0 million or more per month and employs over 120 skilled employees [3] Company Overview - Microbix specializes in proprietary biological products for human health, particularly in the global diagnostics industry [3] - The company produces critical ingredients such as antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are sold in over 30 countries, supported by a network of international distributors [3] - The company is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada [3] Product Development - Microbix develops proprietary products including Kinlytic® urokinase, a biologic thrombolytic drug, and reagents for molecular diagnostic testing [4] - The company’s QAPs and QUANTDx products support clinical lab accreditation and diagnostic workflows [3][4] Event Information - The Muskoka Capital Event is organized by Capital Event Management Ltd., featuring public and private companies and a range of investors [5] - The event aims to foster relationships that lead to financings and increased awareness within the investment community [5]

Core Insights - Microbix Biosystems Inc. and EMQN CIC have launched a program to enhance the identification of patients with gene variants affecting the metabolism of Clopidogrel, a widely prescribed antiplatelet drug [1][2] Group 1: EQA Program Details - The new External Quality Assessment (EQA) program aims to ensure proficiency in Point-of-Care Tests (POCTs) that identify three gene variants of the Cytochrome P450 CYP2C19 enzyme, which are critical for determining appropriate Clopidogrel dosing [2][4] - Over 20% of individuals carry these gene variants, which can lead to either overdosing or underdosing of Clopidogrel, posing significant health risks [2][3] Group 2: Market Context - Clopidogrel is prescribed to over 15 million patients annually in the U.S. alone, indicating a substantial market for pharmacogenomic testing to optimize treatment and minimize risks associated with improper dosing [3] - The EQA program will provide participants with three samples every two months, totaling 18 samples per year, to ensure ongoing accuracy in genetic testing [4] Group 3: Company Contributions - Microbix is supplying quality assessment products (QAPs™) for the EQA program, which will assist in evaluating the accuracy of genetic tests and support safe prescription practices [4][5] - The collaboration with EMQN and Copan aims to enhance the quality of genetic testing, with Microbix expanding its role in the field of pharmacogenomics alongside its established presence in infectious diseases and oncology [5][7] Group 4: Company Background - Microbix Biosystems Inc. is a life sciences innovator with over 120 employees, generating revenues of approximately C$2.0 million or more per month, and is involved in manufacturing critical ingredients for the global diagnostics industry [7][8] - The company is ISO 9001 & 13485 accredited and has a presence in over 30 countries, supported by a network of international distributors [8]

Core Insights - Microbix Biosystems Inc. and Labquality Oy have launched a novel external quality assessment (EQA) program aimed at improving the accuracy of clinical laboratories in identifying HPV-associated head and neck cancers [1][4] - The EQA program is introduced at the 2025 European Society for Clinical Virology meeting and addresses the need for proficiency checks in laboratories performing HPV-related diagnostics [1][4] Group 1: Industry Context - Head and neck cancers (HNCs) are increasingly common, particularly in males, with over 300,000 cases diagnosed annually in North America and Western Europe, representing approximately 4% of all cancers [2] - Accurate identification of HPV-driven HNCs is crucial as these patients have better prognoses, influencing treatment decisions [2] Group 2: EQA Program Details - The EQA program utilizes Microbix's QAPs™ mimetics of HNC patient samples, which include both immunohistochemical (IHC) and PCR targets, to assess laboratory competency [3][5] - A pilot study involving 32 clinical laboratories revealed significant discrepancies in p16 IHC staining protocols, highlighting the need for improved diagnostic accuracy through reflex testing [4] Group 3: Company Profiles - Microbix Biosystems Inc. specializes in creating proprietary biological products for human health, targeting revenues of C$ 2.0 million or more per month, and is involved in the global diagnostics industry [7] - Labquality Oy provides external quality assessment services to over 8,000 customers in more than 60 countries, focusing on enhancing laboratory proficiency and patient care [9]

Core Insights - Microbix Biosystems Inc. and Labquality Oy have launched a new external quality assessment (EQA) program aimed at improving the accuracy of clinical laboratories in identifying head and neck cancers associated with HPV [1][4] Group 1: Industry Context - Head and neck cancers (HNCs) are increasingly common, particularly in males, with over 300,000 cases diagnosed annually in North America and Western Europe, representing about 4% of all cancers [2] - Accurate identification of HPV-driven HNCs is crucial as these patients have better prognoses, influencing treatment decisions [2] Group 2: EQA Program Details - The EQA program was developed to address the lack of proficiency checks for clinical labs working with FFPE samples, which are used for diagnosing HNCs [3] - Microbix created QAPs™ that mimic HNC patient samples, containing both IHC and PCR targets, to support the EQA program [5] - A pilot study involving 32 clinical laboratories revealed significant discrepancies in p16 IHC staining protocols, highlighting the need for improved diagnostic accuracy through reflex testing [4] Group 3: Company Profiles - Microbix Biosystems Inc. specializes in creating biological products for human health, with revenues targeting C$ 2.0 million or more per month and a focus on the global diagnostics industry [7] - Labquality Oy provides EQA services to over 8,000 customers in more than 60 countries, emphasizing quality in clinical laboratories and point-of-care testing [9]

Core Insights - Microbix Biosystems Inc. hosted Ontario's Minister of Public and Business Service Delivery and Procurement, Stephen Crawford, to showcase its biotechnology facilities and discuss advancements in diagnostics that can enhance health outcomes and reduce healthcare costs for Ontarians [1][2] - The company has received over C$ 2.0 million in grant funding from the Ontario Together Funds, which has supported the development of state-of-the-art manufacturing capabilities and healthcare products [1][3] - Microbix supplied over 2 million units of Viral Transport Medium (VTM) to Ontario during the pandemic years of 2021 and 2022, including a significant emergency order of 1.2 million units in December 2021 [1] Company Overview - Microbix is an Ontario-based life sciences innovator with over 120 skilled employees, producing proprietary biological products for human health [3][4] - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are distributed in over 30 countries and are supported by a network of international distributors, with various accreditations including ISO 9001 & 13485 and U.S. FDA registration [3][4] Product Development - Microbix develops proprietary products such as Kinlytic urokinase, a thrombolytic drug for treating blood clots, and reagents for molecular diagnostic testing [4] - The company emphasizes its commitment to innovation and the development of Ontario-made products that contribute to global health [2][3]

Core Insights - Microbix Biosystems Inc. reported disappointing financial results for Q3 and YTD 2025, with significant declines in revenue and net loss compared to the previous year [1][2][6] Financial Performance - Q3 revenue was $3.5 million, a 31% decrease from $5.1 million in Q3 2024, driven by a 44% drop in antigen sales and a 9% decline in QAPs sales [3][11] - Year-to-date (YTD) revenue was $14.8 million, down 22% from $19.1 million in YTD 2024, with antigen revenues up 11% but QAPs revenues down 25% [7][11] - Gross margin for Q3 was 41%, down from 54% in the previous year, primarily due to a less favorable product mix [4][11] - YTD gross margin was 56%, down from 63% in YTD 2024, affected by lower sales of higher-margin products [8][11] Operating Expenses - Operating expenses in Q3 increased by 22% compared to Q3 2024, influenced by lower investment income and the absence of grant income [5][11] - YTD operating expenses rose slightly due to increased investment in R&D and sales and marketing activities [8][11] Net Loss and Cash Flow - The company reported a net loss of $1.6 million for Q3, compared to a net income of $246,746 in Q3 2024 [6][11] - YTD net loss was $765,150, a significant decline from a net income of $3.1 million in YTD 2024 [9][11] - Cash used in operating activities was $1.9 million for Q3, compared to cash provided of $604,064 in Q3 2024 [6][11] Financial Position - As of June 30, 2025, the company had strong cash and equivalents of $12.1 million, with a current ratio of 9.73 and a debt to equity ratio of 0.30, both improved from the previous year [10][11] Corporate Outlook - Management remains cautious about the outlook for the remainder of fiscal 2025, particularly due to reduced sales into China [2][12] - The company aims to drive sales growth across all business lines while improving gross margins and bottom-line results [12]